Atara Biotherapeutics hit with Nasdaq $50M MVLS warning

Atara Biotherapeutics, Inc. received a Nasdaq notice that it no longer meets the $50 million minimum market value of listed securities (MVLS) required for continued listing on the Nasdaq Global Select Market.

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. received a Nasdaq notice that it no longer meets the $50 million minimum market value of listed securities (MVLS) required for continued listing on the Nasdaq Global Select Market.

Nasdaq reviewed the company’s market value over the last 30 consecutive business days and found it below this threshold. Atara has until October 27, 2026 (a 180-day compliance period) to regain compliance. If its MVLS closes at or above $50 million for at least 10 consecutive business days (and potentially up to 20 days at Nasdaq’s discretion), Nasdaq will confirm renewed compliance. The company’s shares continue trading under the symbol “ATRA” while it evaluates options, which may include applying to transfer to the Nasdaq Capital Market. If compliance is not regained by the deadline, Nasdaq may move to delist the shares, a decision Atara could appeal to a Hearings Panel.

Positive

• None.

Negative

• Nasdaq listing deficiency: Atara Biotherapeutics no longer meets Nasdaq’s $50 million minimum market value of listed securities requirement and faces potential delisting if compliance is not regained by October 27, 2026.

Insights

Equity Markets & Listing Standards Analyst

Nasdaq has flagged Atara for falling below its $50M market value listing standard, starting a 180-day cure period.

Atara Biotherapeutics is currently out of compliance with Nasdaq’s $50 million MVLS requirement after its market value stayed below that level for 30 consecutive business days. This triggers a formal deficiency process but does not immediately remove the stock from the Nasdaq Global Select Market.

Under Nasdaq’s rules, Atara has until October 27, 2026 to regain compliance. It must have MVLS of at least $50 million for 10 straight business days, though Nasdaq can require up to 20 days. The company mentions possibly seeking a transfer to the Nasdaq Capital Market, which generally has less stringent standards.

If Atara does not meet the requirement by the Compliance Date, Nasdaq can begin delisting proceedings, and the company would need to appeal to a Hearings Panel to seek continued listing. The practical impact for investors will depend on whether Atara can support a higher market value or secure a different Nasdaq tier before October 27, 2026.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Key Figures

Minimum MVLS requirement: $50 million Review period before notice: 30 consecutive business days Compliance period length: 180 calendar days +3 more

6 metrics

Minimum MVLS requirement $50 million Nasdaq Listing Rule 5450(b)(2)(A) threshold for Global Select Market

Review period before notice 30 consecutive business days Period during which Atara’s market value was below $50 million

Compliance period length 180 calendar days Time from notice until October 27, 2026 to regain compliance

Compliance Date October 27, 2026 Deadline to meet Nasdaq’s $50 million MVLS requirement

Required compliant trading days Minimum 10 business days MVLS must close at or above $50 million for this period

Maximum days Nasdaq may require Up to 20 consecutive business days Nasdaq’s discretionary extended period to confirm sustained compliance

Key Terms

market value for listed securities, Nasdaq Global Select Market, Nasdaq Capital Market, Compliance Date, +2 more

6 terms

market value for listed securities financial

"no longer meets Nasdaq’s $50 million minimum market value for listed securities"

Nasdaq Global Select Market financial

"for continued listing on the Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

Nasdaq Capital Market financial

"could include applying for a transfer to The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

Compliance Date regulatory

"until October 27, 2026 (the “Compliance Date”), to regain compliance"

The compliance date is the specific day by which a company must meet a legal, regulatory, contractual or stock-exchange requirement. Think of it like a deadline to pass an inspection or satisfy a contract term: if the company meets the deadline, normal operations continue; if it misses it, investors may face fines, changed contract terms, delisting, or other financial consequences. Investors watch these dates because they can trigger material changes in risk, cash flow, or share liquidity.

Hearings Panel regulatory

"the Company may appeal the delisting determination to a Hearings Panel"

A hearings panel is a review body at a stock exchange that hears the case when the exchange has decided a company no longer qualifies to keep its shares listed. The company presents a plan to regain compliance, and the panel decides whether the listing continues, on what conditions, and for how long. The decision can keep a stock trading or end its listing.

forward-looking statements regulatory

"contains forward-looking statements within the meaning of the safe harbor provisions"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did Atara Biotherapeutics (ATRA) receive a Nasdaq non-compliance notice?

Atara Biotherapeutics received a Nasdaq notice because its market value of listed securities stayed below the required $50 million threshold for 30 consecutive business days. This violates Nasdaq Listing Rule 5450(b)(2)(A) for the Nasdaq Global Select Market and starts a formal compliance period.

What deadline does Atara Biotherapeutics (ATRA) have to regain Nasdaq compliance?

Atara has until October 27, 2026 to regain compliance with Nasdaq’s $50 million market value requirement. This 180-day compliance period starts from the April 30, 2026 notice and defines when Nasdaq may move toward delisting if compliance is not restored.

What must Atara Biotherapeutics (ATRA) do to satisfy Nasdaq’s $50 million MVLS rule?

To regain compliance, Atara’s market value of listed securities must close at $50 million or more for at least 10 consecutive business days. Nasdaq may, in its discretion, ask for up to 20 consecutive days before confirming long-term compliance.

Does the Nasdaq notice immediately affect trading in Atara Biotherapeutics (ATRA) stock?

The notice has no immediate effect on trading. Atara’s common stock continues to trade on the Nasdaq Global Select Market under the symbol “ATRA” while the company works within the compliance period to address the deficiency.

What options might Atara Biotherapeutics (ATRA) consider to remain listed on Nasdaq?

Atara states it will monitor its market value and may consider options such as applying to transfer to the Nasdaq Capital Market. A successful transfer could allow continued Nasdaq trading under different standards if the company meets that market’s listing criteria.

What happens if Atara Biotherapeutics (ATRA) cannot regain compliance by October 27, 2026?

If Atara does not regain compliance by the October 27, 2026 deadline, Nasdaq will issue a written notice that its securities are subject to delisting. Atara could then appeal the delisting determination to a Nasdaq Hearings Panel for further review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:05 PM EDT Learn about SEC filing dates

0001604464false00016044642026-04-302026-04-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

Atara Biotherapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36548	46-0920988
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
1280 Rancho Conejo Blvd
Thousand Oaks, California				91320
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (805) 623-4211

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ATRA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On April 30, 2026, Atara Biotherapeutics, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets Nasdaq’s $50 million minimum market value for listed securities (“MVLS”) requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”) for continued listing on the Nasdaq Global Select Market based on Nasdaq’s review of the market value of the Company’s listed securities for the last 30 consecutive business days.

In accordance with Nasdaq Listing Rule 5810(c)(3)(C) (the “Compliance Period Rule”), the Company has been provided a period of 180 calendar days, or until October 27, 2026 (the “Compliance Date”), to regain compliance with the MVLS Requirement. If, at any time before the applicable Compliance Date, the Company’s MVLS closes at $50 million or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the MVLS Requirement. Nasdaq may, however, in its discretion, require the Company to demonstrate compliance for a longer period, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

The Notice has no immediate effect on listing of the Company's common stock on the Nasdaq Global Select Market, and the Company’s common stock will continue to trade on Nasdaq Global Select Market under the symbol “ATRA” at this time.

The Company intends to actively monitor the market value of its listed securities. The Company may evaluate and consider available options for regaining compliance with the MVLS Requirement, which could include applying for a transfer to The Nasdaq Capital Market. However, there can be no assurance that the Company will take any specific action or be able to regain compliance with the MVLS Requirement. In the event the Company does not regain compliance with the MVLS Requirement by the Compliance Date, Nasdaq will provide written notification to the Company that its securities will be subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intentions, plans and expectations with respect to the Notice and the MVLS Requirement, the Company’s ability to regain and maintain compliance with the MVLS Requirement and other applicable Nasdaq continued listing requirements, the actions the Company may take in response to the Notice, and the continued listing of the Company’s common stock on the Nasdaq Global Select Market. These forward-looking statements are based on management’s current expectations and are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied in such statements, including the risks described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ATARA BIOTHERAPEUTICS, INC.
Date:	May 1, 2026	By:	/s/ AnhCo Thieu Nguyen
			AnhCo Thieu Nguyen, Ph.D. President and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer)

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.3 KB